Literature DB >> 10511122

Direct block of Ca2+ channels by calmidazolium in cultured vascular smooth muscle cells.

M Sunagawa1, H Yokoshiki, T Seki, M Nakamura, P Laber, N Sperelakis.   

Abstract

We investigated the action of calmidazolium (CMZ), an inhibitor of calmodulin (CaM), on the L-type Ca2+ currents (ICa(L)) of cultured vascular smooth muscle (VSM) cells (A7r5 cell line), by using the whole-cell voltage-clamp method. All experiments were conducted at room temperature (24-25 degrees C). The peak IBa (Ca2+ channel current with 5 mM Ba2+ as charge carrier) was evoked every 15 s by a test potential to +10 mV from a holding potential of -60 mV. To elevate intracellular free Ca2+ concentration ([Ca]i) to pCa 6.5, the pipette solution contained a Ca2+-EGTA buffer (pCa 6.5) to allow equilibration with the cells. Bath application of 1 microM CMZ reduced the peak amplitude of IBa to 36.7+/-4.9% (n = 8); maximal effect occurred within 7-8 min. Peak IBa continued to decrease even after washing out the CMZ. Recovery of IBa was not observed even after 10 min of washout. Even in presence of an peptide inhibitor of CaM-dependent protein kinase-II (5.2 microM) in the pipette solution, CMZ inhibited IBa to 27.8 +/-5.3% (n = 7). To exclude the possibility that other Ca2+/ CaM-dependent kinases and phosphatases may regulate Ca2+ channel activity, we examined the effect of CMZ on IBa when [Ca]i was reduced by use of Ca2+/EGTA-buffered pipette solutions. At pCa approximately equal to 10 (10 mM EGTA and only contaminant Ca2+), CMZ inhibited IBa to 33.4+/-5.9% (n = 14) with a median inhibitory concentration (IC50) value of 0.29 microM. The activation curve (pCa approximately equal to 10) was shifted in the positive direction by 6.3 mV; the inactivation curve was shifted in the negative direction by 5.0 mV. CMZ decreased IBa progressively during repetitive step depolarizations. CMZ did not slow the rate of recovery from inactivation. In conclusion, CMZ inhibits Ca2+ channel current in a use-dependent manner. This inhibition is independent of CaMK-II and other Ca2+/CaM-dependent pathways. Therefore it is likely due to direct blockade of Ca2+ channels by CMZ. CMZ may reduce the outer surface charge and block the open state of the Ca2+ channels.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10511122     DOI: 10.1097/00005344-199910000-00003

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  6 in total

1.  Ca2+/calmodulin-dependent protein kinase II potentiates ATP responses by promoting trafficking of P2X receptors.

Authors:  Guang-Yin Xu; Li-Yen Mae Huang
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-03       Impact factor: 11.205

Review 2.  Regulation of ion channels in myocardial cells and protection of ischemic myocardium.

Authors:  N Sperelakis; M Sunagawa; H Yokoshiki; T Seki; M Nakamura
Journal:  Heart Fail Rev       Date:  2000-06       Impact factor: 4.214

3.  Calmodulin kinase pathway mediates the K+-induced increase in Gap junctional communication between mouse spinal cord astrocytes.

Authors:  M H De Pina-Benabou; M Srinivas; D C Spray; E Scemes
Journal:  J Neurosci       Date:  2001-09-01       Impact factor: 6.167

4.  Calmidazolium and arachidonate activate a calcium entry pathway that is distinct from store-operated calcium influx in HeLa cells.

Authors:  Claire M Peppiatt; Anthony M Holmes; Jeong T Seo; Martin D Bootman; Tony J Collins; Fraser McDonald; H Llewelyn Roderick
Journal:  Biochem J       Date:  2004-08-01       Impact factor: 3.857

5.  Calmodulin Bidirectionally Regulates Evoked and Spontaneous Neurotransmitter Release at Retinal Ribbon Synapses.

Authors:  Chao-Qun Liang; Gong Zhang; Lei Zhang; Si-Yun Chen; Jun-Nan Wang; Ting-Ting Zhang; Joshua H Singer; Jiang-Bin Ke
Journal:  eNeuro       Date:  2021-01-06

6.  A Covalent Calmodulin Inhibitor as a Tool to Study Cellular Mechanisms of K-Ras-Driven Stemness.

Authors:  Sunday Okutachi; Ganesh Babu Manoharan; Alexandros Kiriazis; Christina Laurini; Marie Catillon; Frank McCormick; Jari Yli-Kauhaluoma; Daniel Abankwa
Journal:  Front Cell Dev Biol       Date:  2021-07-08
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.